Till innehåll

Newsroom

The latest news and updates from Oncopeptides

In the spotlight

November 5, 2026
Oncopeptides publishes Q3 report 2026
Investor
Regulatory
Read more

Latest press releases

November 4, 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

CompanyScience
October 9, 2026

Invitation to Oncopeptides’ investor webcast following positive glioblastoma data

CompanyInvestor

Latest news

November 12, 2026
Comment on the Q3 Report and EU approval for third line treatment

CEO Sofia Heigis and CFO Henrik Bergentoft comment on the Q3 report – sales up 41 percent to SEK 28.5 million and, for the first time, more than SEK 100 million in rolling twelve-month sales – and on the EU approval for the third line of treatment, which doubles the addressable patient population, how the launch looks in Germany, Italy and Spain, and why the German price negotiation affects the rest of Europe.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode

Upcoming events

12
Dec
2026
December 12, 2026
ASH
Congress
December 12–15, 2026
68th ASH Annual Meeting and Exposition
New Orleans, Louisiana, and online.
12
Feb
2027
February 12, 2027
EMMA
Congress
February 12–13, 2027
The congress is the 34th edition of European Multiple Myeloma Academy (EMMA 2027)
Madrid, Spain
Select language or region
Region

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care